about
Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cellsSynergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinomaOverexpression of cyclin A inhibits augmentation of recombinant adeno-associated virus transduction by the adenovirus E4orf6 protein.Gene therapy for superficial bladder cancer.Recombinant AAV-directed gene therapy for type I glycogen storage diseases.Transduction of folate receptor cDNA into cervical carcinoma cells using recombinant adeno-associated virions delays cell proliferation in vitro and in vivo.Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein.Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products.Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector productionStable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectorsAdeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood.Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression.DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors.Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.Gene therapy for type I glycogen storage diseasesDNA virus replication compartments.Recombinant junctions formed by site-specific integration of adeno-associated virus into an episome.Emerging Targets in Photopharmacology.Spatiotemporal control of gene expression in mammalian cells and in mice using the LightOn system.Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers.
P2860
Q33678754-4E274DAD-A74F-49BD-A6A9-AF31E6F47197Q33811260-3B6C233C-4DF6-47D0-B04D-F203B559121EQ33824969-21CECFF0-C100-40C3-9668-5F66AC997D0EQ34734147-07E6CBCD-3D23-4E58-8F14-0E8F795CEA36Q35078590-FEC5200B-97EE-499E-9841-F74B9B8E1DDEQ35763351-90D5CD46-CE14-4DA4-8E01-CF33CDFBF95DQ35799349-42C0C394-6338-4124-9001-710E3E279D72Q35837075-09CB9F03-CF65-4D48-B4A5-ED8613DAE295Q35877884-352F4338-4C18-47C4-AFBF-922B69F4FE00Q35891981-1AAD51F9-A5F8-46F6-8CCE-2E5DE090BA14Q36159178-3D76D48C-8D19-4B2D-919E-68628A7A39C6Q36362722-B6B38AA9-CF6D-4A3A-A47E-0F0933120991Q36363237-685DDFF2-503D-4B26-8E7C-C4746EAA66B4Q36599393-180E463B-DD59-4C3B-B20C-B0A077AEA812Q36638167-DA6E5C9B-6A0E-443E-BD35-DF0F6EFAA1E3Q36663364-33006657-9F03-4692-BEEC-FFC4F22D02F9Q36789527-40220F23-2C58-4ACC-A044-2A0D52B39537Q38164528-76673EF3-9C3C-4CB2-9AE5-9BADC2E328B6Q38290022-830AF9C6-1EC6-4E2C-9C92-EA729D8DE880Q38845495-C7C6581F-ED7E-4E6E-A117-CEE9453F5D4EQ39128170-DC05797F-1934-41FC-8B0E-E5945664C4B8Q39873805-F04801AD-5B89-42CE-9071-6BBA542F0DB0
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Adeno-associated virus vectors.
@ast
Adeno-associated virus vectors.
@en
type
label
Adeno-associated virus vectors.
@ast
Adeno-associated virus vectors.
@en
prefLabel
Adeno-associated virus vectors.
@ast
Adeno-associated virus vectors.
@en
P1476
Adeno-associated virus vectors.
@en
P2093
P304
P356
10.1016/0958-1669(92)90082-T
P577
1992-10-01T00:00:00Z